CSI Market
Sign In | Register

Iteos Therapeutics Inc (ITOS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ITOS quarterly Cash Flow →
Observing cash flow movements over recent quarters helps explain how Iteos Therapeutics Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2024)
12 Months 		(Dec 31 2023) (Dec 31 2022) (Dec 31 2021) (Dec 31 2020)
Operating Activities
Income-134.41
Depreciation & amortization1.24
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation29.94
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total-2.06
Fair Value Adjustment For Preferred Stock Tranche Rights And Anti Dilution Warrant Liabilities-
Deferred Rent Adjustments-
Increase Decrease In Grants Receivable-0.83
Increase Decrease In Research And Development Tax Credit Receivable-2.58
Net Accretion Of Available For Sale Debt Securities-11.52
Change In Operating Lease Right Of Use Assets-0.01
Increase Decrease In Accrued Clinical Trial Costs11.72
Increase Decrease In Unrecognized Tax Benefits5.79
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Employee Related Liabilities1.90
Increase (Decrease) in Accounts Payable-2.45
Increase (Decrease) in Accrued Liabilities0.79
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.42
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities3.88
Discontinued operations0.00
Net Cash flow from Operating Activities-98.18
Investing Activities
Capital Expenditures-1.66
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities391.31
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments-520.80
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-131.15
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.20
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.45
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-251.99
Payments For Initial Public Offering Costs-
Preferred Stock Accretion Of Redemption Discount-
Settlement Of Preferred Stock Tranche Right-
Deferred I P O Costs In Accounts Payable-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents251.45
Capital Expenditure Included In Accounts Payable-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability0.54
Proceeds From Issuance Of Common Stock And Pre Funded Warrants-
Proceeds From Issuance Of Common Stock And Warrants119.99
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities122.24
Effect of exchange rate on cash flow-1.93
Discontinued operations0.00
Free Cash Flow-99.84
Total Cash Flow-109.02
4 historic quarters locked

Sign in to unlock the full Iteos Therapeutics Inc cash flow history.

Sign In Create Free Account

About Iteos Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-25-033066

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License